Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGM - Delayed Quote USD

Immuneering Corporation (IMRX)

Compare
1.2700
+0.0200
+(1.60%)
At close: April 17 at 4:00:01 PM EDT
1.2985
+0.03
+(2.24%)
After hours: April 17 at 7:42:46 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
--
--
--
316.9520
2,079.9610
Cost of Revenue
--
--
--
158.1220
1,153.0730
Gross Profit
--
--
--
158.8300
926.8880
Operating Expense
64,071.6550
64,071.6550
58,413.2850
51,904.1690
34,812.9590
Operating Income
-64,071.6550
-64,071.6550
-58,413.2850
-51,745.3390
-33,886.0710
Net Non Operating Interest Income Expense
2,593.3000
2,593.3000
3,606.9960
1,014.4560
169.8990
Other Income Expense
441.4930
441.4930
1,334.2690
216.8440
-127.0630
Pretax Income
-61,036.8620
-61,036.8620
-53,472.0200
-50,514.0390
-33,843.2350
Tax Provision
--
--
--
--
-307.4850
Net Income Common Stockholders
-61,036.6080
-61,036.6080
-53,471.6220
-50,513.5680
-33,535.7480
Diluted NI Available to Com Stockholders
-61,036.6080
-61,036.6080
-53,471.6220
-50,513.5680
-33,535.7480
Basic EPS
-1.97
-2.04
-1.88
-1.91
-2.46
Diluted EPS
-1.97
-2.04
-1.88
-1.91
-2.46
Basic Average Shares
29,536.8070
29,981.5650
28,416.5580
26,386.8640
13,612.6770
Diluted Average Shares
29,536.8070
29,981.5650
28,416.5580
26,386.8640
13,612.6770
Total Operating Income as Reported
-64,071.4010
-64,071.4010
-58,412.8870
-51,744.8680
-33,886.0690
Rent Expense Supplemental
--
--
--
--
108
Total Expenses
64,071.6550
64,071.6550
58,413.2850
52,062.2910
35,966.0320
Net Income from Continuing & Discontinued Operation
-61,036.6080
-61,036.6080
-53,471.6220
-50,513.5680
-33,535.7480
Normalized Income
-61,036.6080
-61,036.6080
-53,471.6220
-50,513.5680
-33,535.7480
Interest Income
2,593.3000
2,593.3000
3,606.9960
1,014.4560
169.8990
Net Interest Income
2,593.3000
2,593.3000
3,606.9960
1,014.4560
169.8990
EBIT
-64,071.6550
-64,071.6550
-58,413.2850
-51,745.3390
-33,886.0710
EBITDA
-63,686.5810
-63,686.5810
-58,061.2020
-51,468.0870
-33,726.9990
Reconciled Cost of Revenue
--
--
--
158.1220
994.0010
Reconciled Depreciation
385.0740
385.0740
352.0830
277.2520
159.0720
Net Income from Continuing Operation Net Minority Interest
-61,036.6080
-61,036.6080
-53,471.6220
-50,513.5680
-33,535.7480
Normalized EBITDA
-63,686.5810
-63,686.5810
-58,061.2020
-51,468.0870
-33,726.9990
Tax Rate for Calcs
--
--
--
--
0
12/31/2021 - 7/30/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TVRD Tvardi Therapeutics, Inc.
17.04
-5.65%
 
XLO Xilio Therapeutics, Inc.
0.7516
-0.83%
 
VOR Vor Biopharma Inc.
0.6500
0.00%
 
RLMD Relmada Therapeutics, Inc.
0.2898
-0.75%
 
VTYX Ventyx Biosciences, Inc.
1.0700
+0.94%
 
LIPO Lipella Pharmaceuticals Inc.
2.4000
+0.42%
 
GLUE Monte Rosa Therapeutics, Inc.
4.5500
+3.17%
 
INAB IN8bio, Inc.
0.1609
+2.09%
 
TENX Tenax Therapeutics, Inc.
5.32
-0.56%
 
OMGAQ Omega Therapeutics, Inc.
0.0550
+10.00%